(株)免疫生物研究所の貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|---|---|---|
| 東証GRT | 医薬品 | 4570/E00986 | Immuno-Biological Laboratories Co.,Ltd. |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|---|---|---|---|---|---|---|---|---|
| 2015/04/17 | 日証協 | 163,030株 | -4% | 10,700株 | -58.2% | 198,339株 | -4.25% | 14,300株 | -59.49% |
| 2015/04/10 | 日証協 | 169,830株 | +22.33% | 25,600株 | +52.38% | 207,139株 | +21.39% | 35,300株 | +29.3% |
| 2015/04/03 | 日証協 | 138,830株 | +6.77% | 16,800株 | 0% | 170,639株 | +6.56% | 27,301株 | +1850.07% |
| 2015/03/20 | 日証協 | 128,230株 | -4.4% | 1,800株 | 0% | 166,439株 | -2.4% | 800株 | 0% |
| 2015/03/13 | 日証協 | 134,130株 | 0% | 0株 | 0.00% | 170,539株 | -0.29% | 0株 | 0.00% |
| 2015/03/06 | 日証協 | 134,130株 | -8.34% | 11,800株 | -56.62% | 171,039株 | -5.1% | 0株 | -100% |
| 2015/02/27 | 日証協 | 146,330株 | +24.08% | 27,200株 | +138.6% | 180,239株 | +9.13% | 7,400株 | -39.34% |
| 2015/02/20 | 日証協 | 117,930株 | -7.16% | 11,400株 | +1325% | 165,159株 | -7.61% | 12,200株 | +771.43% |
| 2015/02/13 | 日証協 | 127,030株 | +1.44% | 800株 | -77.78% | 178,759株 | +0.56% | 1,400株 | -48.15% |
| 2015/02/06 | 日証協 | 125,230株 | -4.64% | 3,600株 | +1700% | 177,759株 | -1.33% | 2,700株 | +145.45% |
| 2015/01/30 | 日証協 | 131,330株 | -4.85% | 200株 | 0% | 180,159株 | +0.61% | 1,100株 | -89% |
| 2015/01/23 | 日証協 | 138,030株 | -3.09% | 0株 | -100% | 179,059株 | -1.05% | 10,000株 | +81.82% |
| 2015/01/16 | 日証協 | 142,430株 | -20.58% | 5,400株 | 0% | 180,959株 | -6.8% | 5,500株 | +83.33% |
| 2015/01/09 | 日証協 | 179,340株 | 0% | 0株 | 0% | 194,159株 | +0.36% | 3,000株 | +1400% |
| 2014/12/30 | 日証協 | 179,340株 | -7% | 0株 | -100% | 193,459株 | -1.83% | 200株 | -98.69% |
| 2014/12/26 | 日証協 | 192,840株 | -4.51% | 5,500株 | -76.89% | 197,069株 | +4.45% | 15,220株 | +508.8% |
| 2014/12/19 | 日証協 | 201,940株 | +13.87% | 23,800株 | +112.5% | 188,669株 | +0.27% | 2,500株 | +8.7% |
| 2014/12/12 | 日証協 | 177,340株 | +3.62% | 11,200株 | +433.33% | 188,169株 | +4.56% | 2,300株 | +283.33% |
| 2014/12/05 | 日証協 | 171,140株 | -0.58% | 2,100株 | 0% | 179,969株 | -0.44% | 600株 | -40% |
※株式分割は考慮していませんのでご注意ください。